New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
07:55 EDTQSII, QSII, RPTP, RPTP, HTWR, HTWR, CVD, CVD, MDVN, MDVN, IDIX, IDIX, ACHN, ACHN, NVS, NVS, ALR, ALR, SNTA, SNTALeerink to host a conference
Global Healthcare Conference 2013 is being held in New York on February 13-14 with webcasted company presentations to begin on February 13 at 8 am; not all company presentations may be webcasted. Webcast Link
News For QSII;ALR;NVS;ACHN;IDIX;MDVN;CVD;HTWR;RPTP;SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
09:15 EDTRPTPOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTRPTPRaptor downgraded to Underperform from Perform at Oppenheimer
Oppenheimer analyst Chris Marai downgraded Raptor Pharmaceuticals to Underperform with an $8 price target. A takeout of the company is unlikely at current valuation levels, Marai tells investors in a research note. He recommends selling the stock.
July 1, 2015
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
June 23, 2015
10:00 EDTALROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:09 EDTSNTASynta says Hsp90 cancer treatment 'therapeutically advantageous'
Subscribe for More Information
08:03 EDTMDVNMedivation lowered expectations skews risk/reward to upside, says UBS
UBS noted Medivation shares have been weak since ASCO but believes the risk reward has been skewed to the upside. The firm said its thesis is different from consensus as they believe the company's pipeline advancement this year could drive multiple expansion if Xtandi sales can at least remain flat. UBS reiterated its Buy rating and $142 price target on Medivation shares.
07:36 EDTACHNJMP Securities to hold a conference
Subscribe for More Information
06:13 EDTALRAlere upgraded to Buy from Neutral at Goldman
Goldman upgraded Alere to Buy and increased its price target to $60 from $50. The firm believes management's focus on improving the cost structure and potential for improved execution is underappreciated. Goldman sees margin leverage driven by new product launches, manufacturing and sourcing initiatives, and slowing regulatory headwinds. Further, potential divestitures of non-core assets will continue to de-leverage the balance sheet.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use